The human immunodeficiency virus (HIV)-1 protease inhibitor saquinavir inhibits proteasome function and causes apoptosis and radiosensitization in non-HIV-associated human cancer cells

Cancer Research

Volumn 62, Issue 18, 2002, Pages 5230-5235

  Pajonk, Frank ^a   Himmelsbach, Judith ^a   Riess, Katrin ^a   Sommer, Alfred ^a   McBride, William H ^b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC AGENT; GAMMA INTERFERON; GREEN FLUORESCENT PROTEIN; HYBRID PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE; PROTEASOME; PROTEINASE INHIBITOR; SAQUINAVIR;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IONIZING RADIATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONTENT; RADIOSENSITIZATION;

ANIMALS; APOPTOSIS; HIV PROTEASE INHIBITORS; HUMANS; MACROPHAGES; MALE; MICE; NF-KAPPA B; PEPTIDE HYDROLASES; PROSTATIC NEOPLASMS; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; SAQUINAVIR; TUMOR CELLS, CULTURED;

EID: 0037105651     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. HIV-protease inhibitors
2. HIV-1 protease inhibitors
3. HIV protease inhibitor ritonavir: A more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833
4. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter
5. Human immunodeficiency virus protease inhibitors serve as substrates for multidrug transporter proteins MDR1 and MRP1 but retain antiviral efficacy in cell lines expressing these transporters
6. Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi’s sarcoma
7. Short-lived green fluorescent proteins for quantifying ubiquitin/proteasome-dependent proteolysis in living cells
8. A proteolytic system that compensates for loss of proteasome function
9. Kinetic characterization of the chymotryptic activity of the 20S proteasome
10. Ionizing radiation and short wavelength UV activate NF-‰B through two distinct mechanisms
11. Apoptosis and radisensitization of Hodgkin’s cells by proteasome inhibition
12. Role of the MDR-1-encoded multiple drug resistance phenotype in prostate cancer cell lines
13. Apoptosis induction resulting from proteasome inhibition
14. The proteasome in cancer biology and treatment
15. The ubiquitin-proteasome proteolytic pathway
16. Selective inhibitors of the proteasome-dependent and vacuolar pathways of protein degradation in Saccharomyces cerevisiae
17. Prostate carcinoma cell death resulting from inhibition of proteasome activity is independent of functional Bcl-2 and p53
18. Inhibition of ubiquitin-proteasome pathway activates a caspase-3-like protease and induces Bcl-2 cleavage in human M-07e leukaemic cells
19. Proteasome inhibitors induce mitochondria-independent apoptosis in human glioma cells
20. Ubiquitinproteasome inhibition enhances apoptosis of human pancreatic cancer cells
21. Proteasome inhibitors: A novel class of potent and effective antitumor agents
22. Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts
23. Enhancement of radiosensitivity by proteasome inhibition: Implications for a role of NF-κB
24. The ubiquitin-mediated proteolytic pathway as a therapeutic area
25. How an inhibitor of the HIV-I protease modulates proteasome activity
26. Inhibition of NF-κB, clonogenicity, and radiosensitivity of human cancer cells
27. Constitutive activation of IκB kinase a and NF-κB in prostate cancer cells is inhibited by ibuprofen
28. Constitutive nuclear factor-κB-ReIA activation is required for proliferation and survival of Hodgkin’s disease tumor cells
29. NF-κB ten years after
30. Permanent occupancy of the human immunodeficiency virus type 1 enhancer by NF-κB is needed for persistent viral replication in monocytes
31. Proteasome inhibition: A new strategy in cancer treatment
32. The proteasome inhibitor PS-341 in cancer therapy
33. Survival of AIDS patients with primary central nervous system lymphoma is dramatically improved by HAART-induced immune recovery
34. HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma
35. Antitumorigenic effects of HIV protease inhibitor ritonavir: Inhibition of Kaposi sarcoma
36. Single daily doses of saquinavir achieve HIV-inhibitory concentrations when combined with baby-dose ritonavir